Article thumbnail

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease

By Ingo J Diel, Jean-Jacques Body, Alison T Stopeck, Saroj Vadhan-Raj, Andrew Spencer, Günther Steger, Roger von Moos, François Goldwasser, Amy Feng and Ada Braun

Abstract

BACKGROUND: We compared the activity of denosumab with zoledronic acid for delaying or preventing hypercalcaemia of malignancy (HCM) in patients with advanced cancer and bone metastases or with multiple myeloma. METHODS: Patient-level data were combined from two identically designed, randomised, double-blind, active-controlled, phase III trials of advanced cancer patients with breast cancer and other solid tumours (excluding breast or prostate cancer) or multiple myeloma. End-points included time to first on-study HCM, time to first and subsequent on-study HCM, proportion of patients experiencing HCM and proportion of patients experiencing recurrent HCM. RESULTS: Denosumab significantly delayed the time to first on-study HCM, representing a 37% reduction in the hazard ratio (HR) compared with zoledronic acid (HR, 0.63; 95% confidence interval (CI): 0.41-0.98; P = 0.042) and reduced the risk of developing recurrent HCM (time to first and subsequent on-study HCM) by 52% (rate ratio, 0.48; 95% CI: 0.29-0.81; P = 0.006). The median time on study was 12.9 months. Fewer patients receiving denosumab compared with zoledronic acid experienced an HCM event (1.7% versus 2.7%; P = 0.028). Of the 84 patients experiencing an HCM event, 40% of those receiving zoledronic acid experienced >1 event of HCM compared with 31% of those receiving denosumab. CONCLUSION: Denosumab treatment was more efficacious than treatment with zoledronic acid in delaying or preventing HCM in advanced cancer patients with breast cancer, other solid tumours or multiple myeloma

Topics: Clinic for Oncology and Hematology, 610 Medicine & health
Publisher: Elsevier
Year: 2015
DOI identifier: 10.1016/j.ejca.2015.04.017
OAI identifier: oai:www.zora.uzh.ch:120114
Provided by: ZORA
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://www.zora.uzh.ch/120114 (external link)
  • https://www.zora.uzh.ch/id/epr... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.